KNSA Annual CFO
$13.30 M
+$7.49 M+129.05%
31 December 2023
Summary:
As of January 23, 2025, KNSA annual cash flow from operations is $13.30 million, with the most recent change of +$7.49 million (+129.05%) on December 31, 2023. During the last 3 years, it has risen by +$149.83 million (+109.74%). KNSA annual CFO is now at all-time high.KNSA Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
KNSA Quarterly CFO
-$2.24 M
-$7.40 M-143.27%
30 September 2024
Summary:
As of January 23, 2025, KNSA quarterly cash flow from operations is -$2.24 million, with the most recent change of -$7.40 million (-143.27%) on September 30, 2024. Over the past year, it has dropped by -$19.22 million (-113.16%). KNSA quarterly CFO is now -103.60% below its all-time high of $62.05 million, reached on September 30, 2022.KNSA Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
KNSA TTM CFO
$11.24 M
-$19.22 M-63.09%
30 September 2024
Summary:
As of January 23, 2025, KNSA TTM cash flow from operations is $11.24 million, with the most recent change of -$19.22 million (-63.09%) on September 30, 2024. Over the past year, it has increased by +$13.84 million (+532.46%). KNSA TTM CFO is now -73.52% below its all-time high of $42.47 million, reached on June 30, 2023.KNSA TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
KNSA Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +129.1% | -113.2% | +532.5% |
| 3 y3 years | +109.7% | +92.2% | +107.6% |
| 5 y5 years | +116.4% | +92.4% | +107.1% |
KNSA Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +110.5% | -103.6% | +93.9% | -73.5% | +108.9% |
| 5 y | 5-year | at high | +108.4% | -103.6% | +94.6% | -73.5% | +107.1% |
| alltime | all time | at high | +108.4% | -103.6% | +96.5% | -73.5% | +107.0% |
Kiniksa Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$2.24 M(-143.3%) | $11.24 M(-63.1%) |
| June 2024 | - | $5.17 M(+29.6%) | $30.47 M(+41.3%) |
| Mar 2024 | - | $3.99 M(-7.8%) | $21.55 M(+62.1%) |
| Dec 2023 | $13.30 M(+129.1%) | $4.33 M(-74.5%) | $13.30 M(-611.6%) |
| Sept 2023 | - | $16.99 M(-553.8%) | -$2.60 M(-106.1%) |
| June 2023 | - | -$3.74 M(-12.3%) | $42.47 M(+10.6%) |
| Mar 2023 | - | -$4.27 M(-63.1%) | $38.39 M(+561.0%) |
| Dec 2022 | $5.81 M(-104.6%) | -$11.58 M(-118.7%) | $5.81 M(-486.9%) |
| Sept 2022 | - | $62.05 M(-893.1%) | -$1.50 M(-98.4%) |
| June 2022 | - | -$7.82 M(-78.8%) | -$92.06 M(-25.2%) |
| Mar 2022 | - | -$36.85 M(+95.1%) | -$123.02 M(-2.6%) |
| Dec 2021 | -$126.30 M(-7.5%) | -$18.88 M(-33.8%) | -$126.30 M(-15.0%) |
| Sept 2021 | - | -$28.51 M(-26.5%) | -$148.60 M(-3.8%) |
| June 2021 | - | -$38.78 M(-3.3%) | -$154.42 M(+6.6%) |
| Mar 2021 | - | -$40.12 M(-2.6%) | -$144.86 M(+6.1%) |
| Dec 2020 | -$136.53 M | -$41.19 M(+20.0%) | -$136.53 M(+14.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2020 | - | -$34.32 M(+17.4%) | -$119.51 M(+4.4%) |
| June 2020 | - | -$29.22 M(-8.1%) | -$114.46 M(-9.8%) |
| Mar 2020 | - | -$31.80 M(+31.6%) | -$126.91 M(-19.9%) |
| Dec 2019 | -$158.37 M(+95.5%) | -$24.17 M(-17.4%) | -$158.37 M(-2.1%) |
| Sept 2019 | - | -$29.27 M(-29.8%) | -$161.84 M(+5.7%) |
| June 2019 | - | -$41.68 M(-34.1%) | -$153.06 M(+18.4%) |
| Mar 2019 | - | -$63.26 M(+128.9%) | -$129.30 M(+59.6%) |
| Dec 2018 | -$81.01 M(+61.3%) | -$27.64 M(+34.9%) | -$81.01 M(+5.5%) |
| Sept 2018 | - | -$20.48 M(+14.3%) | -$76.75 M(+14.2%) |
| June 2018 | - | -$17.92 M(+19.7%) | -$67.21 M(+12.9%) |
| Mar 2018 | - | -$14.97 M(-36.0%) | -$59.51 M(+18.5%) |
| Dec 2017 | -$50.22 M(+129.7%) | -$23.38 M(+113.6%) | -$50.22 M(+87.1%) |
| Sept 2017 | - | -$10.94 M(+7.1%) | -$26.84 M(+68.8%) |
| June 2017 | - | -$10.22 M(+79.9%) | -$15.90 M(+179.9%) |
| Mar 2017 | - | -$5.68 M | -$5.68 M |
| Dec 2016 | -$21.87 M | - | - |
FAQ
- What is Kiniksa Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for Kiniksa Pharmaceuticals?
- What is Kiniksa Pharmaceuticals annual CFO year-on-year change?
- What is Kiniksa Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for Kiniksa Pharmaceuticals?
- What is Kiniksa Pharmaceuticals quarterly CFO year-on-year change?
- What is Kiniksa Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for Kiniksa Pharmaceuticals?
- What is Kiniksa Pharmaceuticals TTM CFO year-on-year change?
What is Kiniksa Pharmaceuticals annual cash flow from operations?
The current annual CFO of KNSA is $13.30 M
What is the all time high annual CFO for Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals all-time high annual cash flow from operations is $13.30 M
What is Kiniksa Pharmaceuticals annual CFO year-on-year change?
Over the past year, KNSA annual cash flow from operations has changed by +$7.49 M (+129.05%)
What is Kiniksa Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of KNSA is -$2.24 M
What is the all time high quarterly CFO for Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals all-time high quarterly cash flow from operations is $62.05 M
What is Kiniksa Pharmaceuticals quarterly CFO year-on-year change?
Over the past year, KNSA quarterly cash flow from operations has changed by -$19.22 M (-113.16%)
What is Kiniksa Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of KNSA is $11.24 M
What is the all time high TTM CFO for Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals all-time high TTM cash flow from operations is $42.47 M
What is Kiniksa Pharmaceuticals TTM CFO year-on-year change?
Over the past year, KNSA TTM cash flow from operations has changed by +$13.84 M (+532.46%)